Ken Griffin Longboard Pharmaceuticals, Inc. Put Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Put Options
2 transactions
Others Institutions Holding LBPH
# of Institutions
101Shares Held
34.1MCall Options Held
8.5KPut Options Held
31.1K-
Ra Capital Management, L.P. Boston, MA3.29MShares$111 Million1.34% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.94MShares$99.5 Million0.38% of portfolio
-
Cormorant Asset Management, LP Boston, MA2.79MShares$94.4 Million5.8% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.51MShares$84.9 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.37MShares$80.1 Million0.0% of portfolio
About Longboard Pharmaceuticals, Inc.
- Ticker LBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,586,000
- Market Cap $460M
- Description
- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...